Inflammatix
Top Five Articles on 360Dx Last Week: FDA LDT Rule's Effect on Dx Firms; FDA Clearances; More
Last week, readers were most interested in a story about how diagnostic firms may be impacted by the FDA's final rule on laboratory-developed tests.
Inflammatix Raises $57M in Series E Financing
The company said that it will use the money to support regulatory filings and commercialization of its 30-minute TriVerity Acute Infection and Sepsis Test.
Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up
Immunexpress, Diasorin, Cytovale, and Ad Astra are among the firms that gained clearances or began commercialization of tests in 2023 that could help guide treatment decisions.
Top Five Articles on 360Dx Last Week: Roche, Inflammatix, FDA Capacity for LDT Oversight, More
Last week, readers were most interested in a story about Roche's LightCycler qPCR system, slated to ultimately replace the LightCycler 480.
The firm said it has secured US Food and Drug Administration breakthrough device designation for its test to classify infections and stratify patients by severe disease risk.